Article

Kidney cancer patients make their preference known

Author(s):

If your doctor asked you to choose between equivalent FDA-approved therapies, you would likely base your decision on a treatment's possible side effects and how they might impact your quality of life, especially if you needed to take that treatment for many months or years. In a new study of patients with metastatic kidney cancer, researchers found that quality of life considerations were significantly more important to patients choosing a treatment than to the doctors prescribing it.In the randomized, double-blinded crossover study, 168 patients received Votrient (pazopanib) for 10 weeks followed by a 14-day break and then Sutent (sunitinib) for 10 weeks, or vice-versa. Nearly two-thirds (70 percent) of patients said they preferred Votrient, compared with 22 percent who preferred Sutent, because they had a better quality of life, which included such factors as less fatigue and soreness of the feet, hands, mouth and throat, as well as fewer treatment interruptions, when taking the drug. Eight percent of patients had no preference.The researchers reported that 60 percent of physicians preferred Votrient, compared with 21 percent who preferred Sutent. About 20 percent of doctors had no preference.Speaking at a press briefing at the 48th annual meeting of the American Society of Clinical Oncology in Chicago, Bernard J. Escudier, MD, of the Institut Gustave Roussy in Villejuif, France, called the results "very surprising." "It was a very significant difference," he told reporters.The study was among the first to consider "how patients feel when they take a drug over many months," something that "isn't reflected in traditional adverse event reporting," Escudier said. Patient-reported outcomes will be increasingly be taken into consideration when determining the effectiveness of particular therapies, he added.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.